Preferred Label : HLA-A1-Binding MAGE-1/MAGE-3 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine;
NCIt definition : A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with
human leukocyte antigen (HLA)-A1-binding melanoma-associated antigen peptides MAGE-1
and MAGE-3 with potential immunomodulating and antineoplastic activity. Upon vaccination,
HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine
may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte
(CTL) and antibody responses against MAGE1- and MAGE-3-expressing cancer cells, resulting
in tumor cell lysis. HLA-A1 is an MHC class I molecule that presents antigenic peptides
to CD8 T cells; epitope design restricted to epitopes that bind most efficiently
to HLA-A1 may improve antigenic peptide immunogenicity.;
NCI Metathesaurus CUI : CL416254;
Origin ID : C90570;
UMLS CUI : C2983770;
Semantic type(s)
- concept_is_in_subset
